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1. Introduction 
Allergy includes a variety of different illnesses (rhinitis, conjunctivitis, asthma, urticaria, and 
dermatitis) with a common pathological basis due to the release of chemical mediators such 
as histamine, platelet-activating factor, metabolites of arachidonic acid, and chemotactic 
factors from mastocytes, basophils, and eosinophils. The keyrole of leukotrienes (LTs) as 
mediators in allergic and inflammatory response justifies the new pharmacologic category 
of Cysteinil LT antagonists as possible therapeutic use in other allergic diseases beyond 
asthma (Leonardi et al., 2007).  
Since 1938, known as slow-reacting substances of anaphylaxis (Feldberg & Kellaway, 1938), 
LTs have been products of the arachidonic acid methabolism pathway by the action of 5-
lipoxygenase. LTs are generated by a number of cells including mast cells, eosinophils, 
basophils, and neutrophils, which appear in the airways of patients with asthma and in the 
skin of patients with chronic urticaria (CU). They mediate chemotaxis, vascular 
permeability, edema, eosinophils migration, airway constriction, and smooth muscle 
contraction (Samuelsson et al., 1997). As their effect has a long time efficacy , these 
molecules are defined as “slow reacting substances”. 
Among LTs, LTB4, LTC4, and LTD4 have particularly potent effects. LTB4 is a potent 
chemoattractant for leukocytes and is involved in the migration of granulocytes into tissues 
(Lewis et al., 1990; Wenzel et al., 1997). LTC4 evokes a wheal and flare reaction when 
intradermally injected. LTC4, LTD4, and LTE4 are chemical mediatoris of the inflammation 
involved in the pathogenesis of asthma, the overall biological effects of which are bronchial 
constriction and an increase in both mucus secretion and vascular permeability (Schleimer et 
al., 1986; Wenzel et al., 1990).  
There are two different LT inhibitors/modifiers: 
- LT receptos antagonists (LTRAs; montelukast, zafirlukast, and Pranlukast). 
- 5-Lypoxigenase inhibitor of LT synthesis (zileuton). 
Montelukast and zafirlukast block binding of cysteinil LTs to the cysLT1 receptor in the 
extracellular space. Zileuton inhibits 5-lipoxygenase and therefore all LT synthesis within 
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inflammatory cells. By blocking the actions of LTs, it promotes bronchodilation and 
decreases the inflammatory response.  
Recent studies performed on adult patients suggest that anti-LTs can play an important role 
not only in the acute phase, but also in controlling the chronic development of bronchial 
asthma. Anti-LTs also have been used successfully by some authors to control allergic 
diseases such as rhinitis, atopic dermatitis, chronic urticaria and allergic conjuncitivitis. 
Moreover, recently, new reports have been published concerning other conditions (migraine 
prophylaxis, sleep disorders, inflammatory bowel disease, and nasal polyposis) that 
broaden the future range of clinical applications.  
2. Leukotriene antagonists 
2.1 Leukotriene synthesis 
Leukotrienes are lipidic mediators, synthesised from arachidonic acid, by different reactions 
of the 5-lypoxigenase enzymatic pathway. The specific enzymatic pathway can be different 
in different cellular types and its activation depends on external cellular stimuli. However it 
is well established that the 5-lypoxigenase pathway is more frequently activated in cells 
deriving from the myeloid pathway (Henderson, 1994). The activation of 5-lypoxigenase 
pathway needs a signal of cell activation with mobilization of calcium and the availability of 
arachidonic acid as substrate. This process moreover requires the interaction with a protein 
called FLAP (protein activating the 5-lypoxigenase), important for the presentation of the 
arachidonic acid to the 5-lypoxigenase (Henderson WR Jr, 1994). The activation of the 5-
lypoxigenase, on cellular and nuclear membranes, leads to the production of an instable 
intermediate molecule, known as LTA4, that could be transformed, according to the cellular 
type, in leukotriene B4 or in cysteinil-leukotriene (LTC4, LTD4, LTE4). Recently the gene 
codifying for LTC4 synthase was identified on the chromosome 5q, in a genetic region 
associated with bronchial asthma and atopic diseases (Bigby et al., 1996). 
2.2 Leukotriene modifier drugs 
Members of both types of LT blockers have been approved for use in the USA, Europe, and 
other nations (eg. Japan). The US Food and Drug Administration approved zileuton, a 5-LO 
inhibitor, in 1996, and two LT blockers, zafirlukast and montelukast, in 1996 and 1998 
respectively; pranlukast was approved in Japan in 1995. the efficacy of montelukast, 
zafirlukast, pranlukast, and zileuton on bronchial asthma has been established in numerous 
randomized, controlled, multicenter clinical trials. LT modifiers reduce asthma symptoms, 
short-acting β2-antagonist (SABA) use, and asthma exacerbations, and improve all indexes 
of pulmonary function, as measured by the increases in forced expiratory flow at one second 
(FEV1), peak expiratory flow (PEF), quality of life, and indices of bronchial inflammation 
(blood eosinophils, inflammatory cells in the bronchial mucosa, exhaled nitric oxide, 
substance P, neurokin A, eosinophil cationic protein, and serum myeloperoxidase) (Riccioni 
et al., 2002; Lakomski & Chitre, 2004). 
2.3 Leukotriene receptor antagonist drugs 
Montelukast. Montelukast is an orally bioavailable Cys-LTRA that is usually administered 
once daily. This drug has been approved for long-term treatment of asthma in adults (10 
mg/day) and children age 2 to 14 yr (using lower dosages, depending on the age of the 
child). Therapeutic concentrations do not inhibit cytochrome P450 isoenzymes. The most 
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common adverse effects observed in adults at the 10 mg daily dosage were compatible with 
placebo, and included headache (18.4% vs 18.1%), abdominal pain (2.7% vs 2.4%), and 
cough (2.7% vs 2.4%). Elevations in liver enzymes occurred at a frequency that was 
generally comparable with placebo. The most common adverse effects that occurred in 
children at an incidence of 2% were slightly (but not significantly) higher than placebo. 
These included diarrhea, laryngitis, pharyngitis, nausea, otitis, sinusitis, and viral infections. 
The adverse event profile did not change with prolonged montelukast treatment (Jones et 
al., 1995; Spector & Antileukotriene Working Group, 2001). 
Zafirlukast. Zafirlukast is a Cys-LTRA that is approved for the treatment of asthma in 
children aged 7 yr or older. It is administered orally twice daily and is metabolized by the 
liver; hepatic cytochrome P450 is inhibited by therapeutic concentrations. Therefore, there 
is a risk of drug interactions, and transient elevations of liver enzymes have been 
reported. The most common adverse effects that were comparable in incidence to placebo 
included headache (12.9% vs 11.7%), infections (3.5% vs 3.4%), nausea (3.1% vs 2.0%), and 
diarrhea (2.8% vs 2.1%). Other common adverse effects (eg, pharyngitis, rhinitis, flush 
syndrome, and increased cough) occurred at incidences identical to or lower than placebo 
(Accolate: Manufacturer’s prescribing information, 1999; Spector & Antileukotriene 
Working Group, 2001). 
Pranlukast. Pranlukast is an orally administered Cys- LTRA that is indicated for 
prophylactic treatment of chronic bronchial asthma in pediatric and adult patients. In 
clinical trials, pranlukast was well tolerated with an adverse event profile similar to that of 
the placebo. Gastrointestinal events and hepatic function abnormalities were the most 
common reported adverse effects, but were not significantly different from other LTRAs 
(Spector & Antileukotriene Working Group, 2001; Keam et al., 2003; Yanagawa et al., 2004). 
Zileuton. Zileuton is the only marketed drug with a specific effect on Cys-LT synthesis via 
inhibition of the 5-LO enzyme. It is administered orally 4 times daily and is approved for 
treatment of asthma in patients 12 yr and older. It is metabolized by the cytochrome P450 
isoenzymes and may, therefore, interact with other drugs metabolized by these enzymes, 
such as theophylline and warfarin. The use of zileuton is hampered by the dosing regimen 
and the requirement that liver enzymes be monitored. The adverse event profile in 
controlled clinical trials was generally similar to LTRAs. The most common adverse effects 
compared to placebo included headache (24.6% vs 24.0%), dyspepsia (8.2% vs 2.9%), 
unspecified pain (7.8% vs 5.3%), nausea (5.5% vs 3.7%), abdominal pain (4.6% vs 2.4%), and 
asthenia (3.8% vs 2.4%). Unlike the LTRAs, therapy with zileuton is associated with 
hepatotoxicity, and liver function enzymes should be monitored during treatment. 
Elevations of liver function tests may progress, remain unchanged, or resolve during 
continued treatment. At a dosage of 600 mg, 4 times daily, zileuton carries a pregnancy 
category C classification because of abnormalities noted in rabbit and rat fetuses (McGill & 
Busse, 1996; Spector & Antileukotriene Working Group, 2001). 
3. Leukotriene antagonists in allergic diseases beyond asthma: Recent 
applications of antileukotriene drugs 
Paranasal sinus disease. LTs are inflammatory mediators that have an important role in 
paranasal sinus disease (PSD) and the formation of nasal polyps (NP). Cys-LTs are 
overproduced in asthmatic subjects with chronic hyperplastic rhinosinusistis (CHR) and 
NP (Higashi et al., 2004). In view of the fact that these agents lead to symptoms in 
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asthmatics patients, the use of LTRAs, particularly montelukast and zafirlukast, seems 
appropriate (Parnes, 2003; Steinke et al., 2003). A number of studies have indicated their 
role in inhibiting nasal symptoms in asthmatic patients. In addition, it has been suggested 
that many aspirin-intolerant asthma patients have NP and that treatment with the LTRAs 
results in improvement and resolution of the NP (Parnes & Chuma, 2000; Borish, 2002; 
Arango & Kountakis, 2002; Arango et al., 2002). The LTRAs might be good alternatives to 
the long-term administration of oral steroids, in view of their systemic anti-inflammatory 
effects and acceptable safety profiles (Parnes, 2002; Scadding, 2003; Haberal & Corey, 
2003; Steinke et al., 2004). 
Bronchiolitis. Many published studies have documented increased LTE4 levels in patients 
with infectious diseases due to respiratory syncytial virus (RSV), such as bronchitis, 
pneumonia, and bronchiolitis, suggesting that LTs may be involved. Cys- LTs, in fact, are 
released during RSV infection and may contribute to the inflammatory state (Takahashi et 
al, 2003). In a 36-months, double-blind trial, 130 infants (median age 9 months) who were 
hospitalized with acute RSV bronchiolitis were randomized into 2 parallel comparison 
groups of 5-mg montelukast chewable tablets or matching placebo given for 28 days starting 
within 7 days after the onset of symptoms. Infants in the montelukast group were free of 
symptoms on 22% of the days and nights, which was significantly lower than the placebo 
group, and there were significant reductions in daytime coughing and clinical exacerbations 
compared to the placebo (Khoshoo et al., 2002; Szefler & Simoes, 2003; Bisgaard, 2003, 2004). 
Rhinitis. It is known that 4-11% of people have asthma and 10-30% have allergic rhinitis 
(AR) (Nathan et al., 1997; Von Mutius, 1998). Frequently comorbidities exists among these 
pathologies. Both conditions show the same allergic and proinflammatory mediators such as 
histamine, LTs, cytokines and eosinophils (Vignola et al., 2003).Moreover AR and asthma 
share common triggers as similar inflammatory cascade on exposure to allergen similar 
patterns of early and late-phase responses (Spector, 1997). Consequently, today, a combined 
approach in the managing of asthma and AR is recommended for an optimal strategy. On this 
regard, the new concept of “one-linked airway disease” between AR and asthma has led to LT 
modifiers being prescribed also for AR. In fact, it is well known that cysteinil LTs are common 
mediators as will in upper as in lower airway diseases, cysteinil LT challanges increase 
rhinorrhea in AR and a release of cysteinil LT reduces symptoms in AR (Howarth, 2000).  
Allergic conjunctivitis. Allergic conjuctivitis (AC) is the most frequent form of ocular allergy 
in patients who consult ophthalmologists and allergists (Bhargava et al., 2004; Marmou and 
Raffard, 2004). The severity of the disease ranges from mild itching and redness, as seen in 
seasonal AC, to the serious, vision-threatening forms of ocular allergy that affect the cornea, 
such as atopic keratoconjunctivitis (AK). The pathogenesis of AC involves a complex 
mechanism that centers around IgE-mediated mast cell degranulation and release of multiple 
performed and newly formed inflammatory mediators. The diagnosis of AC is usually a 
clinical one that is made on a thorough history and careful examination (Epstein, 2003). 
Treatment of ocular allergy should begin with conservative measures including allergen 
avoidance, environmental control, ocular irrigation, and cold compresses (Bhargava et al., 
2004). Pharmacotherapy of AC consists of several classes of drugs: antihistamines, mast cell 
stabilizers, NSAIDs, topical steroids, and, in cases of AK, cyclosporine (Marmou and 
Raffard, 2004). Many studies have evaluated the signs and symptoms of coexisting vernal 
keratoconjunctivitis in asthmatic patients treated with oral montelukast. There were 
significant and persistent reductions of ocular signs and symptoms in asthmatic patients 
with vernal keratoconjunctivitis who were treated for 15 days with montelukast. This points 
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to a need for double-blind, placebo-controlled trials to evaluate the potential of this new 
treatment in patients with vernal keratoconjuctivitis (Leonardi and Abelson, 2003; Lambiase 
et al., 2003). 
4. Allergic conjunctivitis and the possible role of nasal allergy 
Disorders of the conjunctiva, where an allergic component plays an important causal role 
are very common. However, the estimations of incidence of ‘allergic conjunctivitis’ and its 
particular forms vary (McGill et al., 1998; Bielory, 2000; Ziskin, 2006; Bielory & Friedlaender, 
2008; Bielory, 2008; Uchio et al., 2008). Seasonal allergic conjunctivitis (SAC) occurs most 
frequently, followed by atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC) 
and perennial allergic conjunctivitis (PAC), whereas giant papillary conjunctivitis (GPC) 
may be seen only sporadically (McGill et al., 1998; Bielory, 2000; Ziskin, 2006; Bielory, 2008; 
Bielory & Friedlaender, 2008; Uchio et al., 2008). SAC and PAC appear in relatively milder 
form, whereas AKC and VKC occur in a more severe bilateral form, where the conjunctivae 
and cornea may also be affected (McGill et al., 1998; Bielory, 2000; Ziskin, 2006; Bielory, 
2008; Bielory & Friedlaender, 2008; Uchio et al., 2008). 
The relationship between the conjunctiva and the nose is a well-known entity (McGill et al., 
1998; Bielory, 2000; Ziskin, 2006; Bielory & Friedlaender, 2008; Uchio et al., 2008;). The 
coexistence of allergic rhinitis and conjunctivitis has repeatedly been reported in the 
literature (McGill et al., 1998; Bielory, 2000; Ziskin, 2006; Leonardi, 2005; Ono & Abelson, 
2005; Bielory & Friedlaender, 2008; Bielory, 2008; Pelikan, 2009, 2010).  
Nasal allergy could cohere with conjunctivitis in various ways. An allergic reaction 
occurring initially in the nasal mucosa may affect the conjunctiva in different ways upon 
involving diverse mechanisms: (i) this reaction leads to release of mediators, cytokines and 
other factors, which can then penetrate to the conjunctiva through the nasolacrimal duct 
(McGill et al, 1998; Bielory, 2000; Sirigu et al., 2000; Paulsen, 2003; Ono & Abelson, 2005; 
Pelikan, 2009 a, 2009 b); (ii) the released factors can also be transported to the conjunctiva by 
the local haematogenic ways (a. maxillaris- pars pterygopalatina,v. facialis, plexus pterygoideus) 
(Dua et al, 1995; Pelikan, 1996; Bielory, 2000; Pelikan, 2009 a, 2009 b); (iii) allergic reactions in 
the nasal mucosa can stimulate the local neurogenic network and released neuropeptides 
may reach conjunctiva along and/or through the appropriate nerves (n. trigemini, n. 
nasociliaris, pterygopalatine ganglion) (Pelikan, 1995; Fujishima et al., 1997; Calonge et al, 2005; 
Zoukhri, 2006; Motterle et al., 2006; Pelikan, 2009 a, 2009 b); and (iv) this reaction and 
released factors can stimulate the local nasal mucosal lymphatic system, ‘nose-associated 
lymphatic tissue’ (NALT), which is able to communicate with the lymphatic tissue of the 
lacrimal system, ‘tear duct-associated lymphatic tissue’ (TALT), ‘lacrimal drainage-
associated lymphoid tissue’ (LDALT), ‘eye-associated lymphatic tissue’ (EALT) and that of 
the conjunctiva, called ‘conjunctiva-associated lymphatic tissue’ (CALT) (Pelikan, 1996; 
Sirigu et al, 2000; Knop & Knop, 2000; Knop & Knop, 2001, Paulsen et al, 2002; Paulsen et al, 
2003; Zoukhri et al, 2006; Pelikan, 2009 a, 2009 b). In this way not only transmission of 
certain signals but also cellular traffic of various cell types, for example, T lymphocytes (Th1 
and Th2) and B cells (plasma cells), can also be realized (Dua et al, 1995; Pelikan, 1996; 
Calder et al, 1999; Bacon, 2000; Magone et al, 2000.; Pelikan, 2002; Helintö, 2004; Ono & 
Abelson, 2005; Baudouin et al, 2005; Stern et al, 2005; Bielory, 2008; Pelikan, 2009 a, 2009 b). 
An additional mechanism that could also play a role in the cellular traffic among the 
particular organ-associated lymphatic tissues is the ‘defective homing’ of the B lymphocytes 
www.intechopen.com
 Conjunctivitis – A Complex and Multifaceted Disorder 
 
116 
(Pelikan, 1996; Mikulowska-Mennis et al, 2001; Pelikan, 2009 a, 2009 b). Diagnostic 
confirmation of hypersensitivity mechanism (s) in the nasal mucosa can be performed by 
various methods, such as skin tests and in vitro estimation of the specific immunoglobulin E 
antibody (Bielory, 2000; Leonardi, 2005; Radcliffe, 2006). However, these tests provide only 
general evidence for the possible existence of an allergic component somewhere in the body 
and not specifically in a particular organ or tissue. Moreover, these tests do not reflect the 
possible participation of local antibodies in the particular organ and do not provide data on 
the dynamic aspects of the hypersensitivity mechanism(s) (Pelikan, 2009).  
Nasal provocation tests (NPTs) combined with registration of the conjunctival parameters 
are able not only to show the causal role of a certain allergen in the nasal mucosa and 
subsequently in the conjunctiva, but also to record quantitatively responses in their dynamic 
and time-related course. (Pelikan, 2009 a, 2009 b). Although the NPTs are a laborious, time-
consuming technique and require special apparatus and facilities, they generate important 
clinical data that cannot be gathered by other tests. By combining of the recorded 
parameters, NPTs are also able to confirm a causal role of one organ in a response of another 
organ, in this case the causal relationship of nasal mucosa and nasal allergy in the reactions 
of the conjunctiva. Significant correlation of the first and repeated NPTs confirms reliable 
reproducibility of this technique (Pelikan 2009 a, 2009 b, 2010). NPTs can also discriminate 
between the participation of the allergy and the non-specific hypereactivity in the patient’s 
complaints. (Pelikan, 2009 a, 2009 b, 2010) Another advantage of NPTs is their ability to 
follow relative parameter values, by comparing the post-challenge with the pre-challenge 
results. From this point of view the NPTs are independent of the absolute parameter values 
that regularly show high variability (Pelikan, 1996; Pelikan, 2002; Pelikan, 2009, 2010). 
Similar motivation is applicable for the conjunctival provocation tests (CPTs) with allergens 
showing an allergic reaction directly in the conjunctiva and its causal participation in the 
conjunctival complaints (Anderson, 1996; McGill et al, 1998). The results of Pelikan et al 
emphasize some important clinical implications. As nasal allergy can induce a secondary 
conjunctival response (CR), allergic rhinitis may not always be seen only as a coexisting 
disorder to allergic conjunctivitis, but in some patients as a causal trigger for the allergic 
conjunctivitis. This fact would implicate existence of two forms of allergic conjunctivitis, a 
‘primary or classical form’ in which the initial allergic reaction and the subsequent steps 
(clinical symptoms) take place exclusively in the conjunctiva, whereas the ‘secondary form’ 
may be induced by an allergic reaction occurring initially in the nasal mucosa and only the 
consequences (clinical symptoms) are displayed by the conjunctiva (Pelikan, 1996; Pelikan, 
2002; Pelikan, 2009 a, 2009 b). The involvement of various types of hypersensitivity in 
allergic conjunctivitis (Anderson, 1996; Pelikan, 1996; McGill, 1998; Calder et al, 1999; 
Bielory, 2000; Bacon, 2000; Magone et al., 2000; Pelikan, 2002; Bonini et al, 2003; Cook, 2004; 
Stahl & Barney, 2004; Baudouin et al., 2005; Ono & Abelson, 2005; Leonardi, 2006; Bielory & 
Friedlaender, 2008.; Bielory, 2008; Pelikan, 2009 a, 2009 b, 2010;) may result in three types of 
CR, immediate, late and delayed, analogous to the three basic types of nasal response (NR). 
(Pelikan, 1996; Pelikan, 2002). 
5. The ocular allergic response and the role of LTs in allergic conjunctivitis 
The burden of allergic conjunctivitis and related allergic diseases have been increasing 
worldwide. It is speculated that environmental factors are essentially responsible for this 
increase. Because of environmental degradation, especially in urban cities within developing 
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countries, children are confronted with an array of new problems of allergic diseases 
including allergic conjunctivitis. Allergic conjunctivitis is a condition seldom associated with 
visual loss; however, it is important from the perspective of quality of life. 
Particulate matter-pollutants, pollen, dust, mold, mite, animal dander, and other proteins, as 
well as dirt and sand, is meant to be blocked from reaching the eye by eyebrows, eyelashes, 
or eyelids. The particles that evade these barriers alight on the ocular surface and are 
buffered by the tear film, the most important barrier the eye has against foreign substances. 
Whatever is not washed away by the tear film eventually reaches the ocular surface. The 
ocular allergic response is caused by exposure of the conjunctiva, the mucus membrane that 
covers the posterior aspect of the eye, to an antigen. Immunologic recognition of intruders 
awakens the body’s defenses, leading to antigen recognition and sensitization, antibody 
activation, and a full-blown over-reactive immunologic response.  
Dry eye and allergic conjunctivitis are chronic inflammatory diseases of the cornea and 
conjunctiva (ocular surface). Dry eye affects 5 million individuals in the United States alone 
and is more prevalent in women than men (Smith et al, 2007). Allergy including seasonal 
allergic conjunctivitis, vernal keratoconjunctivitis, giant papillary conjunctivitis (also known 
as contact lens-induced papillary conjunctivitis), and atopic keratoconjunctivitis affects 20% 
of the population (Ono & Abelson, 2005). Hallmarks of these diseases are symptoms of 
ocular pain and discomfort, and signs of ocular surface inflammation that generate 
inflammatory cytokines and matrix metalloproteinases. These inflammatory mediators lead 
to death of the surface cells of the corneal and conjunctival epithelia (Lemp, 2007) (Figure 1). 
The pathophysiological basis of conjunctivitis and other type I hypersensitivity disorders, 
such as, rhinitis, asthma and dermatitis, relies on the release of chemical mediators from 
inflammatory cells (Holgate 2000). Histamine plays a pivotal role in ocular hypersensitivity 
reactions of both immunological and non-immunological origin, by exerting its effects on 
blood vessels, nociceptive nerves, fibroblasts, epithelial and goblet cells, mainly via 
histaminergic receptor activation in the ocular surface (Abelson & Schaefer, 1993; Leonardi, 
2000). Histamine, being the main early activating molecule of the inflammatory cascade 
leads to the release of late phase reaction mediators, such as nitric oxide (NO) (Meijer et al., 
1996; Ko, 2000). Additionally, the de novo synthesized pro-inflammatory cysteinyl 
leukotrienes (cysLTs) seem to be equally important, their release in tears from patients with 
various forms of conjunctival inflammation having been documented 
(Akman et al., 1998). Thus, histamine, cys-LTs and NO are involved in the inflammatory 
processes associated with type I hypersensitivity reactions, which have two well-defined 
periods. The early phase appears 5–30 min after challenge and it is characterized by 
vasodilatation and increased vascular permeability, attributed mainly to histamine, which 
initiates the production of other mediators, like prostaglandins, leukotrienes (LTs), NO and 
cytokines (Abelson & Schaefer, 1993; Meijer et al., 1996; Weimer et al., 1998). During the late 
phase response, which begins 2–6 h after challenge, overproduction of these secondary 
mediators exacerbates the inflammatory process. 
The pathophysiology of allergic conjunctivitis is not a simple process. New findings suggest 
that a wide range of cytokines, chemokines, proteases and growth factors are involved by 
complex interrelated interactions (Leonardi et al., 2008). In allergic conjunctivitis, there is 
increased tear levels of several chemical mediators such as histamine, tryptase, leukotrienes 
(LTs) and prostaglandins (Ono & Abelson, 2005). In addition, tear levels of LTB4 and LTC4 
were found to be significantly higher in patients with vernal keratoconjunctivitis than in 
controls (Akman et al., 1998). In fact, leukotrienes play a role in the development of seasonal 
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allergic conjunctivitis as well as the more severe forms as vernal keratoconjunctivitis and 








Fig. 1. Images of allergic conjunctivitis in pediatric patients. It is evident the presence of 
conjunctival hyperemia and oedema.  
Dartt DA et al. (2011) showed that cysteinyl leukotrienes LTC4, LTD4, and LTE4 
produced in the conjunctiva during ocular allergy, dry eye disease, or other inflammatory 
diseases of the ocular surface stimulate goblet cell mucous secretion that can contribute to 
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the excess mucous seen in these diseases. The chronic inflammation in these ocular 
surface diseases damages the cornea and conjunctiva, causing chronic pain from exposed 
nerve endings. They demonstrated that cysteinyl-leukotriene-stimulated goblet cell 
secretion was completely blocked by the pro-resolution resolvins RvD1 and RvE1. Thus, 
resolution of inflammation by the production of pro-resolution mediators, namely, RvD1 
and RvE1, can terminate excess goblet cell mucous secretion allowing the ocular surface to 
repair. These results also support the hypothesis that resolution of inflammation is an 
active process. 
6. The use of leukotriene antagonist drugs in the treatment of allergic 
conjunctivitis 
Allergic conjunctivitis, as described above, is a collection of hypersensitivity disorders that 
affect the lid, conjunctiva and cornea. It is characterized by immunoglobulin E (IgE-) 
mediated and/or T-lymphocyte-mediated immune hypersensitivity reactions (Chigbu 
de,2009). These reactions are initiated by binding of an allergen with specific IgE on the 
surface of mast cells. The resultant mast cell degranulation leads to early phase and late 
phase responses. The early phase response develops immediately after exposure to the 
allergen with clinical symptoms and signs such as itching, chemosis and congestion. This is 
followed by the late phase response after 8-24 hours which is characterized by conjunctival 
cellular infiltrations particularly eosinophilia and neutophilia (Miyazaki et al., 2008). The 
pathophysiology of allergic conjunctivitis is not a simple process, and a wide range of 
cytokines, chemokines, proteases and growth factors are involved by complex interrelated 
interactions (Leonardi et al., 2008).  
Treatment of allergic conjunctivitis includes several drug groups such as antihistamines, 
mast cell stabilizers, non-steroidal anti-inflammatory drugs and corticosteroids in resistant 
cases (Bielory and Friedlaender, 2008). However, the increased worldwide prevalence of 
ocular allergy has stimulated expansion of management strategies towards physiologic and 
immunologic drug targets. One of these targets is the leukotrienes (Schultz, 2006). The pro-
inflammatory effects of leukotrienes have been well described in asthma and rhinitis (Sacre 
Hazouri, 2008). Leukotriene receptor antagonists have emerged as important therapeutic 
options that show clinical efficacy in treatment of bronchial asthma 
The ocular allergic response results from exposure of the conjunctiva to an environmental 
allergen and binding with specific IgE on the conjunctival mast cells. The resultant mast 
cell degranulation plays a key role in the pathogenesis of both the early and late phase 
responses of ocular allergy (Leonardi et al., 2008). Compound 48/80 is a non-
immunogenic mast cell degranulating agent that produces manifestations of external 
allergic inflammation when applied topically to the ocular surface (Allansmith et al., 
1989). The degranulation produced by the compound is less extensive but 
morphologically similar to that seen in vernal and giant papillary conjunctivitis. 
Therefore, it can serve as a useful tool for testing ocular anti-inflammatory agents (Udell 
et al., 1989). Studies with compound 48/80 applied topically to rabbit eyes, producing 
allergic inflammatory manifestations that were evident on clinical examination of the eye 
as well as on hystopathological examination of conjunctival specimens, have been 
described in literature to show the efficacy of anti-leukotrienes drugs efficacy in the 
treatment of allergic conjunctivitis. El-Hossary G.G. et al. demonstrated that pretreatment 
of allergic conjunctivitis model rabbits with 0.1% montelukast eye drops exhibited 
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improvement of ocular inflammatory manifestations both clinically and by 
histopathological examination. The improvement was more evident after 24 hours of 
compound application. (El-Hossary et al., 2010). In agreement with the results of this 
study, it was before described that oral montelukast for 15 days produced significant and 
persistent reduction of ocular signs and symptoms in asthmatic patients with vernal 
keratoconjunctivitis (Lambiase et al., 2003). In addition, Oral montelukast combined with 
oral cetirizine were effective in decreasing orbital congestion and inflammation in patients 
with thyroid eye disease (Lauer et al., 2008). Moreover, oral zafirlukast, another 
leukotriene receptor antagonist similar to montelukast, could significantly attenuate the 
development of conjunctival oedema and inhibit the increase in the number of eosinophils 
in rats with experimental allergic conjunctivitis (Minami et al., 2004). 
Regarding topical ocular application of these drugs, topical application of a leukotriene 
receptor antagonist in combination with a cyclooxygenase inhibitor could significantly 
improve inflammatory manifestations in rabbit eyes burned with sodium hydroxide 
(Struck et al., 1995) In addition, Papathanassiou et al. (2004) reported that topical 
application of zafirlukast to rat eyes, challenged with compound 48/80, produced 
significant inhibition of the late phase nitric oxide production of the conjunctival 
hypersensitivity response. The authors concluded that leukotriene receptor antagonists 
might contribute to the management of ocular inflammatory response (Papathanassiou et 
al., 2004). Outside the eye, inhaled montelukast could significantly inhibit the bronchial 
constriction induced by LTC4 and LTD4 with no injury to the lung tissue in an animal 
model of asthma (Muraki et al., 2009) and this demonstrates the therapeutic effectiveness 
and safety of locally applied montelukast. 
Montelukast is a leukotriene receptor antagonist that is currently used to treat persistent 
asthma (Jarvis and Markham, 2000). Although leukotrienes play a role in development of 
allergic conjunctivitis, they are not the only mediators involved in this disease. 
Histamine, tryptase and prostaglandins are also involved in the immediate allergic 
response (Ono and Abelson, 2005). In addition, mast cell degranulation induces 
activation of vascular endothelial cells and thus the expression of several chemokines 
and adhesion molecules that finally lead to the ocular allergic late phase reaction 
(Leonardi et al., 2008). Moreover, conjunctival and corneal epithelial cells and fibroblasts 
may contribute to mounting the allergic inflammation by expressing and producing 
cytokines, chemokines, adhesion molecules and growth factors that maintain local 
inflammation and lead to tissue remodelling (Leonardi et al., 2006). Montelukast was 
reported to significantly attenuate LT-induced degranulation of bone marrow derived 
mast cells (Kaneko et al., 2009). The drug was also found to inhibit the expression of 
vascular endothelial growth factor and its receptors in lung tissue of experimentally 
induced asthma in rats. Vascular endothelial growth factor is over-expressed in vernal 
keratoconjunctivitis and may involve tissue growth and remodelling that occur in severe 
cases of this disease (Asano-Kato et al., 2005).  
In El-Houssary’s study, pre-treatment of allergic conjunctivitis model rabbits with 1% 
prednisolone produced more improvement of the allergic response than montelukast, this 
detected by significant decrease in the clinical scores at all time intervals of examination and 
by marked improvement of the histopathological picture as the conjunctiva appeared fairly 
normal after 24 hours of compound application. The result of this study is expected and 
logical, as topical corticosteroids are very effective in the treatment of allergic conjunctivitis. 
They have a variety of actions that play a role in suppressing the allergic diseases, and their 
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role is well documented in both clinical and experimental situations (Reiss et al., 1996). 
Nevertheless, topical ocular montelukast can be a potential therapeutic drug with a new route 
of administration that can be used for treatment of allergic conjunctivitis. 
Despite the number of pharmacological agents currently used to prevent the clinical 
manifestations of ocular hypersensitivity, there are still continuing efforts aiming at the 
development of more efficacious topical medications to control the most severe episodes of the 
disease (Yanni et al., 1999). Currently, anti-LT therapies are approved only for patients with 
asthma (Leff, 2001), though recent reports support the clinical efficacy of cysLT receptor 
antagonists in patients with rhinitis (Wilson,2001), and more recently in allergic conjunctivitis.  
7. Conclusions 
Allergic conditions are common in all pediatric age groups, and significantly affect the 
health and overall quality of life of children and their families. Although allergies seem 
relatively minor, they often cause considerable disruptions to daily life for pediatric 
patients, including sleep disturbances, limitation of activities, disrupted reading, computer 
work, or outside play, and impaired psychosocial functioning. Making certain that patients 
are properly treated with the appropriate therapy will help to improve their quality of life. 
Familiarity with diagnosis, treatment, and potential complications of common pediatric 
ocular allergic conditions will increase the chances of early intervention and avert 
potentially serious consequences of these diseases. 
Early and accurate detection of ocular allergy syndromes in children presents a challenge in 
the primary care setting, as young children are often unwilling participants in ocular 
examinations. Involvement of pediatric ophthalmologists with specialized training and 
equipment may be necessary to avoid preventable vision loss in more severe cases. It is the 
responsibility of all involved to optimize the treatment of these children suffering from 
allergic disease. 
Topical ocular montelukast can be a potential therapeutic drug with a new route of 
administration that can be used for treatment of allergic conjunctivitis, as new therapeutic 
strategies an add-on therapy in resistant cases of ocular allergic diseases. 
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